ライフサイエンスコーパス: protease inhibition

1 SBT propeptides with respect to its mode of protease inhibition.

2 mor suppressor activity that is unrelated to protease inhibition.

3 preventive and/or therapeutic properties via protease inhibition.

4 Arg32 in the Kunitz-1 domain is critical for protease inhibition.

5 4-beta5 or beta5-beta6 loops are involved in protease inhibition.

6 ructures reveal a similar novel mechanism of protease inhibition.

7 atine-core unit, characteristic for aspartic protease inhibition.

8 nzymes as evidenced from their resilience to protease inhibition.

9 management, inhibition of inflammation, and protease inhibition.

10 ntermediate that may be populated during the protease inhibition.

11 de structural insight into antibody-mediated protease inhibition.

12 pathway (UPP), metallothionein function, and protease inhibition.

13 nprecedented manner in the field of aspartyl protease inhibition.

14 ion does not involve the serpin mechanism of protease inhibition.

15 e optimal choice to study SLPI-based in vivo protease inhibition.

16 s a functional motif characterized by serine protease inhibition activity in a number of whey acidic

17 being shown to display functions beyond both protease inhibition and anti-infective activity, to whic

18 drophilic functionalities as P2' show potent protease inhibition and antiviral activities against HIV

19 s has been synthesized and evaluated for HIV protease inhibition and antiviral activity.

20 in domains, suggesting direct involvement in protease inhibition and axonal migration, respectively.

21 ng-based biomarker assay to assess real-time protease inhibition and disease progression in a preclin

22 A tradeoff between serine protease inhibition and growth as well as an indirect tr

23 Protease inhibition and laser confocal microscopy associ

24 Na+/H+ exchange inhibition, protease inhibition, and Ca(2+)-free buffer did not decr

25 ses and proteases, whereas genes involved in protease inhibition, angiogenesis, cross-linking of base

26 ation involving the coagulation response and protease inhibition, as well as lipid transport and meta

27 that of beta-lactones in ClpP peptidase and protease inhibition assays and displayed unique target s

28 epend on cysteine protease activity, because protease inhibition blocks egress but not poration, and

29 ) had modest adverse effects on the cysteine protease inhibition but conferred potent activity agains

30 gment of mature falcipain-2 and suggest that protease inhibition, but not the mediation of folding, i

31 nd in neutrophil granules) is the target for protease inhibition by alpha1-antitrypsin, and its unopp

32 Protease inhibition by Glu-Asp-Leu is dependent on a pro

33 key roles in determining the specificity of protease inhibition by plasma serpins.

34 evented by anti-CD18 mAb, R15.7, and also by protease inhibition by PMSF.

35 Protease inhibition by secretory leukocyte protease inhi

36 Protease inhibition by serpins requires a large conforma

37 thermophoresis and analyzed acceleration of protease inhibition by these molecules.

38 the molecular mechanisms that drive cysteine protease inhibition by vinyl sulfones, the binding speci

39 Protease inhibition did not affect the release of active

40 Protease inhibition did not increase BRCA1 synthesis, no

41 restoration of expression via proteasome and protease inhibition did not rescue activity.

42 helix and strand 5A must be displaced during protease inhibition, displacement of strand 1C is requir

43 bin A-sheet is crucial for the last steps of protease inhibition either by affecting the rate of RCL

44 Serine protease inhibition greatly reduces the severity of pers

45 f alternative linkers led to greatly reduced protease inhibition; however, further functionalization

46 mechanism of caspase inhibition, as well as protease inhibition in general.

47 p (RSL) suggests that the role of the RSL in protease inhibition is more complex than that of present

48 ver a novel mechanism whereby loss of serine protease inhibition leads to lung lymphocyte accumulatio

49 easome inhibition and not serine or cysteine protease inhibition, likely through positive changes lat

50 to the potent mitogen Con A, suggesting that protease inhibition may inhibit T cell activation in vit

51 erized with respect to inhibition of various proteases, inhibition mechanisms, membrane permeability,

52 oxomicin in restoring function suggests that protease inhibition might have therapeutic value for thi

53 We describe a new serine protease inhibition motif in which binding is mediated b

54 bond-mediated, active site-directed, serine protease inhibition motifs is revealed in a set of over

55 njury and post-injury treatment with TTX and protease inhibition on proteolysis of the NaCh alpha-sub

56 on and was used to demonstrate the effect of protease inhibition on the quaternary structure of the e

57 Either protease inhibition or MT1-MMP siRNA depletion moderatel

58 t the autophagic vacuoles accumulating after protease inhibition or prolonged vinblastine treatment s

59 57-kDa zymogens in the BHK media shared MMP protease inhibition patterns and MMP-2 immunoreactivitie

60 Furthermore, the protease inhibition profile of Ced-3 was similar to the

61 ibition or off-target serine and/or cysteine protease inhibition remains unresolved.

62 Protease inhibition rescued the nuclear piston mechanism

63 D50 values of 0.32 and 0.75 microM for HIV-1 protease inhibition, respectively, and two other inhibit

64 Results from the protease inhibition studies and the site-directed mutage

65 We analyzed the effects of protease inhibition, substrate modification, and neurona

66 Here, we present a novel mechanism of protease inhibition that relies on active-site-directed

67 e findings extend our view on multicomponent protease inhibition that until now has mainly relied on

68 revious research has revealed legumain (C13) protease inhibition via a carboxy-extended phytocystatin